Illumina, Inc. (ticker: ILMN, exchange: NASDAQ Global Select Market (.O))
News Release -
Solexa to Conduct Technology Workshop at 12th Annual Chips to Hits Conference
HAYWARD, Calif. & CAMBRIDGE, England, Sep 08, 2005 (BUSINESS WIRE) -- Solexa, Inc. (Nasdaq:SLXA) today announced that Gary
Schroth, Ph.D., Director of Expression Applications R&D, will conduct
a technology workshop on the use of Solexa's DNA Cluster
Sequencing-By-Synthesis (SBS) technology for comprehensive digital
gene expression profiling. Dr. Schroth's workshop entitled,
"Generating Cost-Effective Digital Genome-Wide Expression Analysis
using Cloned Single-Molecule Arrays(TM)," will be presented at the
12th Annual Chips to Hits(R) Conference on Tuesday, September 13, 2005
beginning at 3:45 p.m. Eastern Time in Boston.
"DNA Cluster-SBS technology has the advantage of producing highly
accurate, reproducible and quantitative readouts of the full
complement of activated genes or small RNA in a particular tissue
without requiring advance knowledge of gene structure or coding
sequence," stated John West, Solexa's chief executive officer.
"Furthermore, we expect that Solexa's technology will generate this
digital data at costs comparable to those of analogue methods
currently in use."
Solexa is developing DNA Cluster-SBS as a next-generation
sequencing technology that can be used in a range of expression
applications, both as a discovery and a validation tool. Among the
primary applications of the platform will be tag-based digital
expression profiling, full-transcriptome sequencing for the discovery
and quantification of transcript variants and coding SNPs, and
discovery and quantification of small RNA species. Since Solexa's
approach to expression profiling does not require any a priori
knowledge of the transcriptome, the technology will enable
sequencing-based expression profiling of any transcript, from any
gene, in any organism, including those with poorly annotated genomes.
Solexa expects to introduce its Cluster-SBS instruments in late 2005
and to begin commercial sale in 2006.
Solexa, Inc. is developing and preparing to commercialize a new
genetic analysis instrument system which will be used to perform a
range of analyses including whole genome resequencing, gene expression
analysis and micro-RNA analysis. We expect Solexa's first-generation
technology to generate over a billion bases of DNA sequence per run
and to enable whole genome resequencing below $100,000 per sample,
making it the first platform to reach this important milestone.
Solexa's longer-term goal is to reduce the cost of human re-sequencing
to a few thousand dollars for use in a wide range of applications from
basic research through clinical diagnostics. The Company expects to
introduce its first instrument system by the end of 2005. For further
information, please visit www.solexa.com.
This press release contains "forward-looking" statements,
including statements related to the current views of Solexa management
as to future products, product development including the commercial
introduction of the Company's novel genetic analysis technology, the
expansion and success of Solexa's commercial application of its
genomics technologies, the availability of adequate funding for Solexa
and the future financial performance of Solexa. Any statements
contained in this press release that are not statements of historical
fact may be deemed to be forward-looking statements. Words such as
"believes," "anticipates," "plans," "predicts," "expects,"
"envisions," "hopes," "estimates," "intends," "will," "continue,"
"may," "potential," "should," "confident," "could" and similar
expressions are intended to identify forward-looking statements. There
can be no assurance that such expectations of any of the
forward-looking statements will prove to be correct, and actual
results could differ materially from those projected or assumed in the
forward-looking statements. There are a number of important factors
that could cause the results of Solexa to differ materially from those
indicated by these forward-looking statements including, among others,
risks detailed from time to time in the Company's SEC reports,
including its Annual Report on Form 10-K for the year ended December
31, 2004 and its Form 10-Q for the quarter ended June 30, 2005. Solexa
does not undertake any obligation to update forward-looking
SOURCE: Solexa, Inc.
Omead Ostadan, 510-670-9300
European Media Contact:
Sue Charles, +44 (0)20 7886 8152
Lippert/Heilshorn & Associates
Jody Cain (firstname.lastname@example.org)
Bruce Voss (email@example.com)
U.S. Media Contact:
Mark Stuart (firstname.lastname@example.org)